Lobe Science公司通过发行3.8M股票以0.05科多巴元清偿了与相关方的137K美元债务,提高了其资产负债表。 Lobe Sciences settled $137K debt with a related party by issuing 3.8M shares at C$0.05, boosting its balance sheet.

Lobe Science Ltd.通过发行380万共同股,每股0.05科多巴元,加强资产负债表和保存现金,结清了相关当事方的137 130美元债务。 Lobe Sciences Ltd. settled $137,130 in related party debt by issuing 3.8 million common shares at C$0.05 each, strengthening its balance sheet and conserving cash. 这项交易涉及Clearway Global, LLC -- -- 与公司董事有联系的债权人 -- -- 根据加拿大规则,不受正式估值和股东批准的限制。 The transaction, involving Clearway Global, LLC—a creditor linked to a company director—was exempt from formal valuation and shareholder approval under Canadian rules. 股份有四个月的持有期。 Shares are subject to a four-month hold period. 该公司的重点是通过Cynaptec和Altemia子公司进行神经、血病和罕见疾病治疗,在不断筹资努力中强调战略增长。 The company, focused on neurological, hematological, and rare disease therapies through subsidiaries Cynaptec and Altemia, emphasized strategic growth amid ongoing financing efforts. 没有遵守豁免规定,这些股份不在美国登记出售。 The shares are not registered for sale in the U.S. without compliance with exemptions.